Abbonarsi

Increased cardiovascular risk associated with diabetes in Dallas County - 17/08/11

Doi : 10.1016/j.ahj.2005.10.016 
Sandeep R. Das, MD, MPH, Patrice A.C. Vaeth, DrPH, Harold G. Stanek, MS, James A. de Lemos, MD, Robert L. Dobbins, MD, PhD, Darren K. McGuire, MD, MHSc
Donald W. Reynolds Cardiovascular Clinical Research Center at the University of Texas Southwestern Medical Center in Dallas, TX 

Reprint requests: Darren K. McGuire, MD, MHSc, Division of Cardiology, University of Texas Southwestern Medical Center, 5909 Harry Hines Blvd, St. Paul HA9.133, Dallas, TX 75235-9047.

Riassunto

Background

Diabetes mellitus is a major public health problem in the United States. We assess the prevalence of diabetes in Dallas County, quantify the association between diabetes and subclinical cardiovascular disease, and assess the use of evidence-based cardiovascular disease risk-modifying therapies.

Methods

This study uses data from 3392 participants aged 30 to 65 years from the Dallas Heart Study, a probability-based, multiethnic sample of residents living in Dallas County, Texas. Three primary outcomes were examined: (1) diabetes prevalence, (2) adjusted odds ratios for detectable coronary calcium stratified by diabetes diagnosis status, and (3) rates of use of evidence-based cardiovascular disease risk-modifying therapies among subjects with diabetes stratified by diabetes diagnosis status.

Results

The estimated prevalence of diabetes in Dallas County was 7.8%, with >40% of diabetic patients undiagnosed before participation in the Dallas Heart Study. Both previously diagnosed and previously undiagnosed diabetes were independently associated with the presence of coronary artery calcium (diagnosed: OR 3.55, 95% CI 1.56-8.05) (undiagnosed: OR 2.98, 95% CI 1.39-6.39). The rates of use of aspirin, angiotensin-converting enzyme inhibitors, and statins were suboptimal, and blood pressure and low-density lipoprotein cholesterol targets were rarely met, especially among subjects with previously undiagnosed diabetes.

Conclusions

Diabetes is prevalent and is associated with subclinical cardiovascular disease; this association is present even at the time of diagnosis. Despite the cardiovascular risk associated with diabetes, evidence-based risk-modifying therapies continue to be underused, and therapeutic targets remain unmet, especially among people unaware of their diabetes diagnosis.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 The DHS is supported by a grant from the Donald W. Reynolds Foundation. Reagents for fructosamine assay were provided by Roche Diagnostics (Indianapolis, IN). Dr McGuire had full access to all of the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis.


© 2006  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 151 - N° 5

P. 1087-1093 - maggio 2006 Ritorno al numero
Articolo precedente Articolo precedente
  • Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes
  • Aida Jimenez-Corona, Robert G. Nelson, Maurice L. Sievers, William C. Knowler, Robert L. Hanson, Peter H. Bennett
| Articolo seguente Articolo seguente
  • NT–probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non–ST-elevation acute coronary syndromes
  • José Luis Navarro Estrada, Fernando Rubinstein, Maria Cecilia Bahit, Florencia Rolandi, Diego Perez de Arenaza, Jose M. Gabay, Jose Alvarez, Ricardo Sarmiento, Carlos Rojas Matas, Carlos Sztejfman, Alejandro Tettamanzi, Raul de Miguel, Luis Guzman, on behalf of PACS Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.